Ma et al. describe the involvement of the Gram-negative Gammaproteobacteria, Stenotrophomonas maltophilia (SM), in neutropenic hematology patients with fever. These authors showed that this
organism was the fourth most prevalent bacterium associated with infection.
1
Likewise, this pathogen has emerged as a commonly isolated bacterium from sputum
from the lower respiratory tract of people with cystic fibrosis (PwCF).
- Ma L.
- Shen J.
- Jiang H.
- Qian S.
- Zhang J.
- Lan J.
- et al.
Empirical polymyxin B therapy in febrile neutropenic patients with hematological diseases:
a prospective, multicenter, observational clinical study.
J Infect. 2023; https://doi.org/10.1016/j.jinf.2023.01.026
2
In Europe, the European Cystic Fibrosis Society Patient Registry Report, described
SM prevalence rates of 7.1% and 8.9%, in children and adults, respectively.
- Brooke J.S.
Advances in the microbiology of Stenotrophomonas maltophilia.
Clin Microbiol Rev. 2021; 34e0003019https://doi.org/10.1128/CMR.00030-19
3
Whilst there are numerous reports describing the clinical consequences of SM infection,
particularly in relation to virulence and antimicrobial resistance,
Orenti A., Zolin A., van Rens J., Fox A., Krasnyk M., Daneau D., et al. 2022. European cystic fibrosis society patient registry annual report 2020. Available at: 〈https://www.ecfs.eu/sites/default/files/ECFSPR_Report_2020_v1.0%20%2807Jun2022%29_website.pdf〉. [Accessed on 16 Feb 2023].
4
currently there is a paucity of reports on the infection dynamics of Stenotrophomonas maltophilia in PwCF; hence, it was the aim of this study to (i). examine time to first laboratory
reports of SM acquisition, (ii) gender, and (iii) cystic fibrosis transmembrane conductance
regulator (CFTR) mutation type, in association with initial SM isolation.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of InfectionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Empirical polymyxin B therapy in febrile neutropenic patients with hematological diseases: a prospective, multicenter, observational clinical study.J Infect. 2023; https://doi.org/10.1016/j.jinf.2023.01.026
- Advances in the microbiology of Stenotrophomonas maltophilia.Clin Microbiol Rev. 2021; 34e0003019https://doi.org/10.1128/CMR.00030-19
Orenti A., Zolin A., van Rens J., Fox A., Krasnyk M., Daneau D., et al. 2022. European cystic fibrosis society patient registry annual report 2020. Available at: 〈https://www.ecfs.eu/sites/default/files/ECFSPR_Report_2020_v1.0%20%2807Jun2022%29_website.pdf〉. [Accessed on 16 Feb 2023].
- Achromobacter xylosoxidans and Stenotrophomonas maltophilia: emerging pathogens well-armed for life in the cystic fibrosis patients' lung.Genes. 2021; 12: 610https://doi.org/10.3390/genes12050610
Cystic Fibrosis Foundation Patient Registry 2022. 2021 Annual data report, Bethesda, Maryland. Available at: 〈https://www.cff.org/sites/default/files/2021–11/Patient-Registry-Annual-Data-Report.pdf〉. [Accessed on 16 Feb 2023].
- Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients.J Cyst Fibros. 2013; 12: 482-486https://doi.org/10.1016/j.jcf.2012.12.006
- Stenotrophomonas maltophilia – a low-grade pathogen with numerous virulence factors.Infect Dis. 2019; 51: 168-178https://doi.org/10.1080/23744235.2018.1531145
- Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients.Respir Res. 2010; 11: 140https://doi.org/10.1186/1465-9921-11-140
- Cystic fibrosis genotype and bacterial infection: a possible connection.Br J Biomed Sci. 2005; 62: 85-88https://doi.org/10.1080/09674845.2005.11732691
- Stenotrophomonas maltophilia as an emerging ubiquitous pathogen: looking beyond contemporary antibiotic therapy.Front Microbiol. 2017; 8: 2276https://doi.org/10.3389/fmicb.2017.02276
Article info
Publication history
Published online: February 20, 2023
Accepted:
February 17,
2023
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
